Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients (EQUIVOK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03197805|
Recruitment Status : Terminated (Take care recommendations for Her2 equivok patients has changed.)
First Posted : June 23, 2017
Last Update Posted : July 25, 2019
The American Society of Clinical Oncology (ASCO) and the /College of American Pathologists (CAP) recommend that HER2 status (negative or positive) must be determined in all patients with invasive breast cancer. The knowledge of HER2 status will help the oncologist in prescribing or not a HER2-targeted therapy to patients. Presently, two main methods are used to assess HER2 status: immunohistochemistry (IHC, protein expression) and in situ hybridization (ISH, gene expression) in order to classify tumor sample as positive, negative or equivocal. When a tumor is classified HER 2+ by IHC method, a second test is performed using ISH methods (FISH, SISH, CISH). In case of HER2 equivocal result with ISH method (4 ≤HER2 gene number copy <6), the patient is eligible to an anti-HER2 therapy after discussed during MD-MM. This decision should be individualized on the basis of patient status (comorbidities and prognosis) and patient preferences after discussing available clinical evidence.
Based on molecular classification, RNA expression could help to discriminate breast cancer subtypes (luminal A, luminal B, HER2-overexpressed and triple negative). Prosigna is a genomic test, developed by NanoString® based on the PAM50 gene signature, which measures the expression of 50 genes to classify tumors into 1 of 4 intrinsic subtypes and could allow determining the HER2 status.
This study was designed in order to define if such a test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population. In addition, concordance tests will be performed. The aim of this study is to assess the modification decision rate between the first and the second multidisciplinary decision-making meeting in HER2 equivocal patients using genomic testing.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Diagnostic Test: PAM 50 test||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Cohort longitudinal follow up|
|Masking:||None (Open Label)|
|Official Title:||Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment Decision-making in Breast Cancer Patients With an ISH Equivocal HER2 Status- EQUIVOK Study|
|Actual Study Start Date :||October 16, 2017|
|Actual Primary Completion Date :||May 28, 2019|
|Actual Study Completion Date :||May 28, 2019|
Experimental: Use of PAM 50 test in Her2 equivocal breast cancer patient
Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
Diagnostic Test: PAM 50 test
Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
- The modification of therapeutical decision between the first and the second multidisciplinary decision-making meeting (MD-MM) using a genomic testing [ Time Frame: The measure will be realised after the second multidisciplinary decision-making meeting that is about one month after patient's inclusion. ]Percentage of therapeutical strategy changes between the first and the second multidisciplinary decision-making meetings.
- The HER2 overexpression incidence according to RNA genomic profile among equivocal-HER2 patients [ Time Frame: The measure will be done when the genomic test is realised, that is about three weeks after patient's inclusion. ]Percentage of HER2 classified patients using a genomic test among equivocal-HER2 patients
- The concordance between the second multidisciplinary decision-making meeting decision and the HER2 genomic test result [ Time Frame: The measure will be done when the genomic test is realised, that is about three weeks after patient's inclusion. ]Percentage of second multidisciplinary decision-making meeting decision in accordance with genomic test result and reasons justifying discrepancies (check-list and comments)
- To compare results from different ISH methods used [ Time Frame: The measure will be done when the genomic test is realised, that is about three weeks after patient's inclusion.. ]Comparison between all ISH (FISH, SISH, CISH, or DDISH) methods based upon the HER2-eligible classification (Wolff et al 2013)
- The concordance between local and centralized anatomopathologist HER2 status [ Time Frame: The measure will be done when the genomic test is realised,that is about three weeks after patient's inclusion. ]Concordance between local and centralized anatomopathologist HER2 status.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03197805
|CHRU Jean Minoz|
|Besançon, France, 25030|
|Bordeaux, France, 33076|
|Centre François Baclesse|
|Caen, France, 14000|
|Centre Jean Perrin|
|Clermont-Ferrand, France, 63000|
|Centre Georges François Leclerc|
|Dijon, France, 21079|
|CHU Albert Michalon|
|Grenoble, France, 38043|
|Limoges, France, 87042|
|Centre Léon Bérard|
|Lyon, France, 69373|
|Institut Paoli Calmettes|
|Marseille, France, 13009|
|Institut de Cancérologie de Montpellier|
|Montpellier, France, 34298|
|Institut Jean Godinot|
|Reims, France, 51056|
|Institut du Cancer COURLANCY|
|Reims, France, 51100|
|Institut de Cancérologie de l'Ouest|
|Saint-Herblain, France, 44805|
|Centre Paul Strauss|
|Strasbourg, France, 67065|
|Institut Claudius Regaud|
|Toulouse, France, 31059|
|Institut de Cancérologie de Lorraine|
|Vandœuvre-lès-Nancy, France, 54519|
|Principal Investigator:||Marie-Ange MOURET-REYNIER, MD||Centre Jean Perrin|